WebMay 6, 2024 · CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dyno Therapeutics, Inc., a biotechnology company applying artificial intelligence (AI) to gene therapy, today announced a $100 million Series A financing led by Andreessen Horowitz, with participation from a select syndicate of new investors including Casdin Capital, GV, Obvious Ventures and … WebDyno closes $100 million Series A financing led by Andreessen Horowitz PARTNERING & LICENSING Astellas for AAV vectors directed to skeletal and cardical muscle
Dyno Therapeutics Strikes AAV Deal with Roche Worth up to $1 ... - BioSpace
WebDyno Therapeutics is a Biotechnology, Biotechnology Research, and Artificial Intelligence company located in Cambridge, Massachusetts with 129 employees. Find top … WebCurrently working as Founder and Chief Executive Officer at Dyno Therapeutics in Massachusetts, United States. ... Contact Details. Email er*****@dynotx.com. Get Email Address. ... Industry Healthcare, Pharmaceuticals, & Biotech. Get Access to Eric's Email Address & Phone Number. Additional Contacts at Dyno Therapeutics. Eric Kelsic. … fish finder lures
Dyno Therapeutics - Funding, Financials, Valuation & Investors
WebMay 11, 2024 · Dyno Therapeutics is a pioneer in applying artificial intelligence (AI) and quantitative high-throughput in vivo experimentation to gene therapy. The company’s proprietary CapsidMap™ platform ... WebMay 6, 2024 · Dyno’s approach has already proven to be highly prolific here too: the company has signed partnerships, potentially worth over $4 billion in aggregate, to develop next-generation AAV vectors for gene therapy leaders like Sarepta in muscle diseases, Novartis in eye diseases, and Roche/Spark Therapeutics for the central nervous system … fish finder manufacturers